Skeletal muscle pathology in Costello and cardio-facio-cutaneous syndromes: developmental consequences of germline Ras/MAPK activation on myogenesis.

Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics (2014) 1.01

Fibroblast growth factor signaling in mammalian tooth development. Odontology (2013) 0.88

De novo deletion of chromosome 11q12.3 in monozygotic twins affected by Poland Syndrome. BMC Med Genet (2014) 0.83

NF1 is a critical regulator of muscle development and metabolism. Hum Mol Genet (2013) 0.79

Muscle-derived extracellular signal-regulated kinases 1 and 2 are required for the maintenance of adult myofibers and their neuromuscular junctions. Mol Cell Biol (2015) 0.79

Layer specific and general requirements for ERK/MAPK signaling in the developing neocortex. Elife (2016) 0.76

Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome. Biochemistry (2013) 0.76

Skeletal muscle and motor deficits in Neurofibromatosis Type 1. J Musculoskelet Neuronal Interact (2015) 0.75

The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev (2009) 5.53

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science (2006) 3.96

Advocacy groups as research organizations: the PXE International example. Nat Rev Genet (2007) 2.72

Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell (2003) 1.95

Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med (2008) 1.64

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One (2007) 1.56

Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat (2007) 1.56

Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther (2009) 1.46

HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A (2006) 1.39

Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. Am J Med Genet A (2011) 1.24

Neurological complications of cardio-facio-cutaneous syndrome. Dev Med Child Neurol (2007) 1.22

Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet (2009) 1.13

Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. Methods Enzymol (2008) 1.12

Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology (2002) 1.10

Cerebrovascular complications of methamphetamine abuse. Neurocrit Care (2009) 1.09

Cardio-facio-cutaneous syndrome phenotype and del(12q). Am J Med Genet A (2003) 1.07

Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology (2005) 1.06

Genomic alterations that contribute to the development of isolated and non-isolated congenital diaphragmatic hernia. J Med Genet (2011) 1.05

Ring chromosome 15: characterization by array CGH. Hum Genet (2005) 0.97

Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish. Dis Model Mech (2012) 0.96

Autism traits in the RASopathies. J Med Genet (2013) 0.95

Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun (2013) 0.94

Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet (2007) 0.91

Cytogenetic and array CGH characterization of de novo 1p36 duplications and deletion in a patient with congenital cataracts, hearing loss, choanal atresia, and mental retardation. Am J Med Genet A (2008) 0.91

Mating activates NMDA receptors in the medial preoptic area of male rats. Behav Neurosci (2007) 0.90

The diagnosis of Costello syndrome: nomenclature in Ras/MAPK pathway disorders. Am J Med Genet A (2008) 0.88

What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A (2010) 0.88

Adult nemaline myopathy with trabecular muscle fibers. Muscle Nerve (2009) 0.85

Pituicytomas and spindle cell oncocytomas: modern case series from the University of California, San Francisco. Pituitary (2015) 0.84

Ring 21 chromosome and a satellited 1p in the same patient: novel origin for an ectopic NOR. Am J Med Genet A (2003) 0.84

Supernumerary marker chromosomes derived from chromosome 6: cytogenetic, molecular cytogenetic, and array CGH characterization. Am J Med Genet A (2012) 0.83

Peripheral muscle weakness in RASopathies. Muscle Nerve (2012) 0.83

Hypophysitis: a single-center case series. Pituitary (2015) 0.83

Effects of germline mutations in the Ras/MAPK signaling pathway on adaptive behavior: cardiofaciocutaneous syndrome and Noonan syndrome. Am J Med Genet A (2010) 0.82

Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation. Hum Mol Genet (2013) 0.81

LC3 and p62 as diagnostic markers of drug-induced autophagic vacuolar cardiomyopathy: a study of 3 cases. Am J Surg Pathol (2013) 0.81

Xq chromosome duplication in males: clinical, cytogenetic and array CGH characterization of a new case and review. Am J Med Genet A (2005) 0.81

Incidence of microduplication 22q11.2 in patients referred for FISH testing for velo cardiofacial and DiGeorge syndromes. Eur J Hum Genet (2005) 0.81

Juvenile myelomonocytic leukemia in a 16-year-old with Noonan syndrome: case report. J Pediatr Hematol Oncol (2012) 0.80

Cortical ependymoma with unusual histologic features. Clin Neuropathol (2013) 0.80

Lipodermoid in a patient with Emanuel syndrome. J AAPOS (2013) 0.79

Chromosome 3p25 deletion in mother and daughter with minimal phenotypic effect. Am J Med Genet A (2006) 0.79

Reliability and validity testing of automated scoring in obstructive sleep apnea diagnosis with the Embletta X100. Laryngoscope (2014) 0.79

Clarification of previously reported Costello syndrome patients. Am J Med Genet A (2008) 0.78

Variable expression of coxsackie-adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy. Thyroid (2005) 0.78

Detection of single clone deletions using array CGH: identification of submicroscopic deletions in the 22q11.2 deletion syndrome as a model system. Am J Med Genet A (2007) 0.78

RASopathies: unraveling mechanisms with animal models. Dis Model Mech (2015) 0.78

Mutational and functional analysis in human Ras/MAP kinase genetic syndromes. Methods Mol Biol (2010) 0.77

Human coxsackie adenovirus receptor (CAR) expression in transgenic mouse prostate tumors enhances adenoviral delivery of genes. Prostate (2005) 0.77

Interstitial deletion of chromosome 12q: genotype-phenotype correlation of two patients utilizing array comparative genomic hybridization. Am J Med Genet A (2005) 0.77

Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion. Neurologist (2010) 0.76

Craniofacial and dental development in Costello syndrome. Am J Med Genet A (2014) 0.76

Fetal autopsy findings of cardiofaciocutaneous syndrome with a unique BRAF mutation. Pediatr Dev Pathol (2013) 0.76

Duplication of distal 20q: clinical, cytogenetic and array CGH. Characterization of a new case. Clin Dysmorphol (2006) 0.75